Item 2.02.
|
Results of Operations and Financial Condition.
|
On November 9, 2017, Aldeyra Therapeutics, Inc.
(Aldeyra) issued a press release and is holding a conference call regarding its financial results for the quarter ended September 30, 2017. The press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated by reference herein.
Various statements to be made during the conference call are
forward-looking statements under the securities laws, including, but not limited to, statements regarding Aldeyras plans for its product candidates. In some cases, you can identify forward looking statements by terms such as, but
not limited to, may, might, will, objective, intend, should, could, can, would, expect, believe,
anticipate, project, target, design, estimate, predict, potential, aim, plan or the negative of these terms, and similar expressions intended
to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual
results to differ materially from those reflected in Aldeyras forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyras clinical trials, the timing and success of preclinical
studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyras product candidates, and the labeling for any
approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyras product candidates; the size and growth of the potential markets for Aldeyras product candidates and the ability to serve those
markets; Aldeyras expectations regarding Aldeyras expenses and revenue, the sufficiency of Aldeyras cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyras product
candidates; Aldeyras expectations regarding competition; Aldeyras anticipated growth strategies; Aldeyras ability to attract or retain key personnel; Aldeyras ability to establish and maintain development partnerships;
Aldeyras expectations regarding federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries; Aldeyras ability to obtain and maintain intellectual property protection for
Aldeyras product candidates; the anticipated trends and challenges in Aldeyras business and the market in which it operates; and other factors that are described in the Risk Factors and Managements Discussion and
Analysis of Financial Condition and Results of Operations sections of Aldeyras Annual Report on Form
10-K
for the year ended December 31, 2016 and Aldeyras Quarterly Report on Form
10-Q
for the quarter ended June 30, 2017 which are on file with the Securities and Exchange Commission (SEC) and available on the SECs website at www.sec.gov. Additional information will also be set forth
in those sections of Aldeyras Quarterly Report on Form
10-Q
for the quarter ended September 30, 2017, which will be filed with the SEC in the fourth quarter of 2017.
In addition to the risks described above and in Aldeyras other filings with the SEC, other unknown or unpredictable factors also could affect
Aldeyras results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information conveyed on the conference call is provided only as of the date of the call, and Aldeyra
undertakes no obligation to update any forward-looking statements presented on the call on account of new information, future events, or otherwise, except as required by law.
The information in Item 2.02 of this Current Report on Form
8-K
and the Exhibit attached hereto shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as expressly set forth by specific reference in such a filing.